Clinical Indications for PET Myocardial Perfusion Imaging and Myocardial Blood Flow Quantification: An American Society of Nuclear Cardiology (ASNC) Position Statement

Since the publication of the 2016 Position Statement on the Clinical Indications for Myocardial Perfusion PET,¹ a growing body of evidence has reinforced the expanding role of positron emission tomography (PET) in the diagnosis and management of coronary artery disease (CAD). This momentum derives from an enhanced understanding of the unique capabilities of PET myocardial perfusion imaging (MPI) and the use of dynamic PET acquisitions to quantify myocardial blood flow (MBF). Extensive and convincing evidence on its excellent diagnostic accuracy and valuable risk stratification have been demonstrated in multiple clinical studies. As a result, major national and international multi-societal clinical guidelines now classify it as the preferred test, if available.